Tick-Borne Encephalitis Virus NS1 protein is produced entirely from human cell lines. The Tick-Borne Encephalitis Virus NS1 protein has been manufactured in response to a need for a highly purified, concentrated protein for use in serological based diagnostic products. The antigen is in its native folding state, and possesses all post-translational modifications. This advanced approach results in a product which delivers optimal antigenicity due to its human origin.
The Tick-borne encephalitis virus (TBEV) is a Flavivirus which is transmitted to humans through a bite from an infected tick. Tick-borne encephalitis (TBE) is endemic in Europe and Asia with an average of 8,500 cases per year in Europe (wwwnc.cdc.gov/travel/yellowbook/2014/). TBE infected patients typically present with influenza-like symptoms and the disease is neuroinvasive often manifesting as meningitis, encephalitis or meningoencephalitis. Long-lasting or permanent neuropsychiatric sequelae are reported in 10 to 20% of patients.
Tick-Borne Encephalitis Virus NS1 is presented in a hexameric state.
Recombinant protein corresponding to Encephalitis Virus NS1, Tick-Borne, strain Neudoerfl, fused to 6X His-Tag at C-terminal, expressed in 293 human cells
Inactivation:Cells are lysed by sonication and freeze/thawing. Confirmed inactive by no visible growth in permissive media after 5 days compared to positive control.
Storage and Stability:Aliquot to avoid repeated freezing and thawing and store at -70°C. Aliquots are stable for 6 months after receipt. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
Note:No test guarantees a product to be non-infectious. All materials should be handled as if potentially infectious. Generally accepted laboratory practices appropriate for infectious materials should be employed when handling this product.
